SABCS 2021

Hypothesis-generating study in the HER2-enriched…

Re-evaluation confirms old data

The next standard for TNBC?!

Metformin shows no efficacy for most cancer patients

Leading the way for other ct-DNA trials

Benefit only related to chemotherapy?!

Molecular-guided treatment is of value in combination…

Negative results with hope for translational projects

Solved and unsolved controversies of early breast…

Metformin is not an anti-cancer drug

Genomic signatures of DCIS

Critical consideration of the study data is necessary

The risk-adapted decision for or against AI has to be…

Hypothesen-generierende Studie beim HER2-enriched…

E’ solo effetto della chemioterapia?

La metformina non può essere considerata un farmaco…

Negative Ergebnisse, aber Hoffnung für translationale…

Erneute Auswertung bestätigt alte Daten

"Signatures Genomiche " nel carcinoma duttale in situ

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

cTRAK TN: ctDNA monitoring not yet ready for primetime.…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

HER2+ EBC: Chemotherapy free regimens? Extended…

Robust benefit of pembroluzimab in addition to…

PFS improvement with fulvestrant in patients with…

Dato-Dxd for metastatic TNBC

Amazing period for patients with refractory metastatic…

Oral SERDs for early setting and adjuvant therapy

Samuraciclib - new targeted therapy for luminal breast…

Final results of the CPS score subgroup analyses show…

Elacestrant - less than we expected

Very good news for endocrine resistant metastatic…

Precision oncology is beneficial in certain mBC…

Exciting novel therapies for metastatic TNBC

IO + IO without resounding success in the mBC setting

Pioneering study of personalized medicine in advanced…

TROP2 - new target for improved chemotherapy

Reconfirming effect of T-DXd in patients with brain…

Activity of T-Dxd across all Her2-expressing breast…

Which patients will benefit from Pembro in metastatic…

TDXd is very efficient in patients with brain…

Immuntherapy for high tumor mutation burden in…

T-Dxd is also active in patients with brain metastasis

Best of the year: systemic therapy

Pooled analyses shows OS benefit for most subgroups

Dato-DXd new promising ADC

3 updates - 3 new standards of care

More good news for TDXd

Switching with molecular progress improves PFS

Promising results for TNBC patients

Oral SERDs are efficient, but show high progression…

My highlights of 2021 in metastatic breast cancer

Imaging with mass cytometry can provide predictive…

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Chekpoint inhibition in breast cancer

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Risultati promettenti nel tumore al seno triplo…

Samuracyklib – nowe leczenie celowane w rakach…

Best of the Year: Systemtherapie

Résultats prometteurs dans le cancer du sein triple…

Mi retrospectiva del cáncer de mama metastático en 2021

Checkpoint-Inhibition beim Mammakarzinom

L’imaging mass cytometry può aiutare a predire…

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Umstellung bei molekularem Progress verlängert PFS

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Activité du T-DXd dans les metastases cérébrales

T-Dxd aktywny również w przerzutach do mózgu

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

È un grande momento per i pazienti con tumore mammario…

Präzisionsonkologie funktioniert beim mBC

IO + IO ohne durchschlagenden Erfolg beim mBC

Important benefice de l’ajout du pembrolizumab à la…

Neues Target für optimierte Chemotherapie

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Buone notizie per i tumori mammari endocrino resistenti

Werden orale SERDs die Therapie mit Fulvestrant in…

Wegweisende Daten für die personalisierte Medizin beim…

Elacestrant – poniżej oczekiwań

Resultados finales de los análisis de los subgrupos de…

MBC HR+: What is the best option after a CDK4/6i…

Integrating patients perspectives in metastatic breast…

MBC TNBC: Molecular tumor characteristics define the…

Are SERDs a future therapy for endocrine resistant…

New ADCs on the horizon for TNBC patients

Targeting rare mutations in breast cancer - is this the…

Therapy of brain metastasis – can T-DXd be the new SoC?